While achieving brilliant achievements, the company has also thrown out a brilliant profit distribution plan: the company plans to distribute a cash dividend of 65,438+00 yuan (including tax) to all shareholders for every 65,438+00 shares, and at the same time transfer 4 shares to all shareholders for every 65,438+00 shares with capital reserve.
The company said that the COVID-19 epidemic in 2020 disrupted people's daily life and business planning. The management of the company took active and effective measures to make timely adjustments, and put forward the strategy of "calmly analyzing, calmly responding, proceeding in an orderly manner, and being busy without chaos" to turn the crisis into an opportunity. Under the guidance of the strategic deployment of the board of directors, the company's scientific research, production, marketing and other departments focused on core business, and all sectors achieved rapid growth, and the market share of each product and the company's popularity and reputation were significantly improved.
The first prize of national scientific and technological progress promotes the contrarian growth of cardiovascular and cerebrovascular products.
In 2020, the sales revenue of Tongxinluo, Shensong Yangxin Capsule and Qiliqiangxin Capsule * * reached 3.447 billion yuan, which increased against the trend 1 1.3 1% under the influence of adverse factors such as epidemic situation. The company won the first prize of national scientific and technological progress award, and its influence on the market of cardiovascular and cerebrovascular products has been enhanced.
On June 5438+ 10, 2020, the project "Theoretical Construction of Traditional Chinese Medicine and Its Guidance for the Prevention and Treatment of Microangiopathy" completed by Hebei Yiling Medical Research Institute, a subsidiary of the company, won the first prize of National Science and Technology Progress in 20 19, which was the only first prize of National Science and Technology Progress in the medical and health field that year. It mainly involves Tongxinluo, Shensongyangxin Capsule and Qiliqiangxin Capsule, and the academic brand has been greatly improved.
With the promotion of the company's academic brand and the change of marketing model, the scale of sales staff has increased greatly. Through more refined sales management and more accurate academic promotion, the market share has been further enhanced.
Intranet data show that the market share of the company's three innovative patented traditional Chinese medicines, Tongxinluo Capsule, Shensongyangxin Capsule and Qiliqiangxin Capsule, rose from 13.6% in 20 15 years to 15% in the first half of 2020, contributing more than half of the market share of TOP 10 products.
Lianhua insecticidal products have played an important role in epidemic prevention and control at home and abroad.
Huaqing plague products have played an important role in epidemic prevention and control, which not only led to a substantial increase in product sales, but also increased the coverage of blank market in structure, significantly enhanced brand influence and strong market demand, providing impetus for its future growth.
In overseas markets, up to now, Lianhua Qingwen has been registered as a medicine in Indonesia, Mozambique, Thailand, Ecuador, Singapore, Laos, Philippines, Kuwait, Mauritius, Uganda, Mongolia, Zimbabwe, Uzbekistan, China, China, Hong Kong and China, as a dietary supplement and health care product in Russia, Brazil, Romania, Kyrgyzstan and Ukraine, and has been actively circulated in 30 countries.
The investment of R & ampAmpd continues to increase, and the potential of second-line varieties is huge.
In recent years, Yiling Pharmaceutical has continuously increased its investment in scientific research and promoted the close combination of scientific research and production. In 2020, the company's research and development; R&D investment was 737 million yuan, a year-on-year increase of 43.09%; D the proportion of investment in operating income has exceeded 8% year after year. In 2020, R&D institutions will reach1996; D personnel, a year-on-year increase of 26.89%.
"At present, the company has 1 1 patents on traditional Chinese medicine. In addition to cardiovascular and cerebrovascular diseases and lianhua Qingwen, second-line varieties
Dongxing Securities also said in a recent research report that based on the exclusive collateral theory, the company has built a variety of Chinese patent medicine product lines, such as core cardiovascular products and Lianhua Qingyi products, and the second and third line products are also rich in layout. At present, the company's sales staff has completed the structural adjustment according to the product line, and the number of sales staff has greatly expanded. The refinement of terminal coverage and the expansion of grass-roots market have promoted the continuous improvement of product penetration, and the superposition of capacity release and sales upgrade is expected to promote the continuous growth of performance.
In the first quarter, it achieved a "good start", with an increase of 50%-60% above the high base.
18 in March, the company released the 202 1 first quarter performance forecast. It is estimated that the net profit attributable to shareholders of listed companies will be 657 million -7.0 1 billion yuan, up 50%-60% year-on-year; The basic earnings per share is 0.55 yuan/share -0.59 yuan/share, achieving a good start.
As for the reasons for the change in performance, the company said that winning the first prize of national scientific and technological progress has gradually improved the market influence of the company's cardiovascular and cerebrovascular products, and the market demand has steadily increased. At the same time, with the adjustment of the company's sales strategy and the optimization of the marketing organization structure, the sales revenue increased significantly year-on-year. In addition, the brand awareness of Lianhua's plague-clearing products has been greatly improved, the market share has continued to increase, and the sales revenue has achieved good growth compared with the same period last year.
Some market participants believe that the company's performance can achieve rapid growth in the first quarter of last year with a high base, far exceeding market expectations. This also proves to some extent that the epidemic has not only brought periodic benefits to the company, but also opened up medium and long-term development space.
Related question and answer: 10 to 5 shares is good or bad? It's good. In the emerging securities market, investors like to send shares for exchange, and listed companies distribute shares by way of dividends and capitalization to cater to investors. On the other hand, in the mature securities market, listed companies often use cash dividends to distribute profits to ensure the stability of shareholders' income.